Home  /  Resource Library  /  Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Results of a phase III trial investigating of Duvelisib for treatment of relapsed chronic lymphocytic leukemia. (Abstract only)